Lanreotid Viatris

Lanreotide, the active ingredient in Lanreotid Viatris, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed to control hormone excess in patients with acromegaly and to manage tumor growth and hormone‑related symptoms in neuroendocrine tumors and carcinoid syndrome.

GNH USA supplies Lanreotid Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics across global markets worldwide.

Lanreotide is used in endocrine‑related disorders that involve excess hormone secretion or neuroendocrine tumor activity. - Acromegaly: reduces growth hormone and IGF‑1 levels, improving disease control. - Gastroenteropancreatic neuroendocrine tumors: inhibits tumor growth and hormone secretion, stabilizing disease. - Carcinoid syndrome: lessens flushing and diarrhea by blocking serotonin and other vasoactive substances.

Lanreotide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Diarrhea. - Nausea. - Abdominal cramps. - Headache. - Fatigue.

Serious or Rare Side Effects: - Gallbladder disease (biliary sludge or stones). - Hyperglycemia or new‑onset diabetes. - Pancreatitis. - Severe allergic reactions (anaphylaxis, angioedema). - Cardiac arrhythmias. - Severe gastrointestinal perforation.

When prescribing Lanreotide, clinicians should consider several safety precautions to minimize risk. - Assess baseline glucose: monitor blood sugar as Lanreotide can affect glucose metabolism. - Evaluate gallbladder status: patients with gallstones may develop biliary complications. - Monitor for signs of pancreatitis: watch for abdominal pain and elevated enzymes. - Review cardiac history: caution in patients with known arrhythmias. - Adjust dose in renal or hepatic impairment: use with care in severe dysfunction. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid): - Concomitant use with cyclosporine: may increase lanreotide levels and risk of adverse effects. - Combined therapy with other somatostatin analogs: additive hormonal suppression can cause severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Antidiabetic agents (insulin, sulfonylureas): monitor glucose as lanreotide may raise blood sugar. - CYP450 substrates metabolized by the liver: potential changes in drug concentrations. - Hormonal contraceptives: possible reduced efficacy due to altered hormone levels. - Digoxin: monitor for altered plasma levels. - Octreotide: overlapping mechanisms may require dose adjustments.